These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Vaccine; 2009 Mar 26; 27(15):2114-20. PubMed ID: 19356614 [Abstract] [Full Text] [Related]
24. Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine. Martin D, Menschik D, Bryant-Genevier M, Ball R. Drug Saf; 2013 Jul 26; 36(7):547-56. PubMed ID: 23657824 [Abstract] [Full Text] [Related]
25. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Piedra PA, Gaglani MJ, Kozinetz CA, Herschler GB, Fewlass C, Harvey D, Zimmerman N, Glezen WP. Pediatrics; 2007 Sep 26; 120(3):e553-64. PubMed ID: 17698577 [Abstract] [Full Text] [Related]
28. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B, CAIV-T Asthma Study Group. Pediatr Infect Dis J; 2006 Oct 26; 25(10):860-9. PubMed ID: 17006278 [Abstract] [Full Text] [Related]
29. Surveillance for adverse events following receipt of pandemic 2009 H1N1 vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010. Yih WK, Lee GM, Lieu TA, Ball R, Kulldorff M, Rett M, Wahl PM, McMahill-Walraven CN, Platt R, Salmon DA. Am J Epidemiol; 2012 Jun 01; 175(11):1120-8. PubMed ID: 22582207 [Abstract] [Full Text] [Related]
30. Intranasal live attenuated seasonal influenza vaccine: does not challenge current practice. Prescrire Int; 2013 Sep 01; 22(141):201-4. PubMed ID: 24171209 [Abstract] [Full Text] [Related]
33. A US postmarketing evaluation of the frequency and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years: 2009-2010 season. Tennis P, Toback SL, Andrews EB, McQuay LJ, Ambrose CS. Vaccine; 2012 Sep 14; 30(42):6099-102. PubMed ID: 22841479 [Abstract] [Full Text] [Related]
34. The safety of live attenuated influenza vaccine in children and adolescents 2 through 17 years of age: A Vaccine Safety Datalink study. Daley MF, Clarke CL, Glanz JM, Xu S, Hambidge SJ, Donahue JG, Nordin JD, Klein NP, Jacobsen SJ, Naleway AL, Jackson ML, Lee G, Duffy J, Weintraub E. Pharmacoepidemiol Drug Saf; 2018 Jan 14; 27(1):59-68. PubMed ID: 29148124 [Abstract] [Full Text] [Related]
35. Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines. Sarntivijai S, Xiang Z, Shedden KA, Markel H, Omenn GS, Athey BD, He Y. PLoS One; 2012 Jan 14; 7(11):e49941. PubMed ID: 23209624 [Abstract] [Full Text] [Related]